A new study that looked at how liberal vs. restrictive fluid restriction impacts health status for patients with chronic ...

A U.S. court has brought back a patent infringement case between Getinge's Maquet and Johnson & Johnson's Abiomed.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Supira Medical has raised $120 million to complete the clinical development of its temporary heart pump, designed for ...

Background The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with adverse ...

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

The the Court of Justice for the European Union reports a decrease in new IP cases in 2024 despite a 12% increase in overall ...

Johnson & Johnson (NYSE:JNJ) holds one of the longest dividend growth track records in the market, spanning over 62 years.

J&J and Abiomed said the transaction has already been approved by both companies' boards and is expected to close before the end of the first quarter of 2023, subject to regulatory approvals ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Use of two high-risk cardiovascular devices—the Watchman (Boston Scientific) left atrial appendage occluder and the Impella (Abiomed) left ventricular assist device—is highest in the United States ...